New markers and models of premalignancy and the early development of gastric cancer
Using a new model of stomach pre-cancers in mice, Dana-Farber researchers gained important insights into the early events that lead... Read More
Our Impact
Gastric Cancer Foundation improves the lives of people affected by gastric (stomach) cancer by supporting patient education initiatives and innovative research studies to improve treatments and ultimately, find a cure.
Support Research for a Cure
Every contribution to Gastric Cancer Foundation makes a difference. Honor a loved one, make a tribute to someone’s memory, honor a happy occasion by making a meaningful donation.
-
Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors
A study by MD Anderson found that tumors with DNA mismatch repair, including gastric cancer, responded to a combo of... Read More
ALX Oncology’s ALX148 Receives Two Fast Track Designations from FDA for the Treatment of Patients with Head and Neck Squamous Cell Carcinoma and Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
ALX Oncology won fast-track designation from the FDA for its drug ALX148 in the second-line treatment of patients with HER2-positive... Read More
Family History of Gastric Cancer and Helicobacter pylori Treatment
A new study in the New England Journal of Medicine concludes that eradicating H. Pylori in people with a family... Read More
Manish Shah, MD, discusses avelumab’s effectiveness based on results from the JAVELIN 100 study
Manish Shah of Weill Cornell Medicine explains the results of a recent study in which gastric cancer patients given either... Read More
New Report Counters Claims on the Origin of Gastric Cancer
A new study in Gastroenterology suggests that stem cells from the upper part of the stomach cause changes that can... Read More
HIPEC With Cisplatin, Mitomycin, and Paclitaxel for Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology
Gastric cancer patients whose disease had spread to the peritoneum received infusions of mitomycin, cisplatin and paclitaxel into the peritoneum... Read More
More muscle, more protein may improve odds of surviving cancer: study
A review of nearly 150 studies reveals that a diet focused on maintaining muscle mass improves treatment response and survival... Read More
Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: A large cohort study
A study of more than 370,000 veterans with H pylori infections published in Gastroenterology found an increased risk of gastric... Read More
Immunotherapy with Anti-PD-1 Effective for Patients with Solid Tumors
A review of 13 clinical trials published in JAMA Oncology found that patients with solid tumors, including stomach tumors, had... Read More
Mindfulness Programming Improves Sleep Quality, Stress Reduction in Survivors and Caregivers
Mindfulness training lowers stress and enhances sleep and resilience in cancer survivors and and caregivers, according to a new study... Read More
Blood-Based Test Could Help Identify Hard-to-Detect Gastrointestinal Cancers
A blood test that’s being developed to detect cancer at its earliest stages was roughly 90% effective at detecting gastrointestinal... Read More
Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting
At ASCO GI, Leap Therapeutics announced that in a trial of DKN-01 in patients with advanced gastric cancer, elevated expression... Read More
Association of Acupuncture and Acupressure With Improved Cancer Pain
A review of clinical trials reveals that acupuncture and acupressure help reduce pain and opioid usage in cancer patients.
BeiGene bags option on Leap cancer drug, requests PD-1 combination trial
BeiGene and Leap Therapeutics have teamed up to study a combination of an anti-DKK1 antibody with the anti-PD-1 antibody tislelizumab... Read More-
BeiGene bags option on Leap cancer drug, requests PD-1 combination trial
BeiGene and Leap Therapeutics have teamed up to study a combination of an anti-DKK1 antibody with the anti-PD-1 antibody tislelizumab... Read More 
Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
Blueprint Medicines won FDA approval for Ayvakit (avapritinib), the first treatment for gastrointestinal stromal tumors (GISTs) that targets platelet-derived growth... Read More
Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint
The new targeted drug Enhertu showed a promising response rate in a trial of patients with HER2-positive gastric cancer.
Light to moderate amount of lifetime alcohol consumption and risk of cancer in Japan
A Japanese study published in the journal Cancer reports that even moderate alcohol consumption raises the risk of cancer and... Read More
Gritstone posts ‘one of the most potent immunogenic-responses for a neoantigen vaccine’
Two patients with gastroesophageal cancer responded well to Gritstone Oncology’s immune-stimulating treatment in an early trial.
Monthly Newsletter
We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.